Bear Stearns reiterates Pfizer at outperform

Pfizer Inc. was reiterated by Bear Stearns analyst John Boris at an outperform rating and a $30 price target as the company prepares to launch Lyrica. The launch is underappreciated, Bear Stearns said, making for a good reason to buy the stock. Sales of Lyrica in 2010 are projected at $2.4 billion. And regulatory setbacks in 2005 will provide catalysts in the first quarter of this year. Shares of the New York City pharmaceutical company were up 3 cents, or 0.12%, at $24.58 on volume of 42,276,300 shares versus the three-month running average of 38,731,900 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.